Annals of the Rheumatic Diseases: B-cell removal treatment of proliferative lupus nephritis with obituzumab: a randomized, double-blind, placebo-controlled trial

Random trials have shown that type I anti- CD20 rituximab and orrelizumab failed to show benefit in proliferative lupus nephritis (LN) .
Orbituzumab is a humanized type II anti- CD20 monoclonal antibody, which is more effective than rituximab in inducing B cell depletion.
The results of a preclinical study showed that orbituzumab is better than rituximab Monoclonal antibodies are more effective in treating LN .
Therefore in this study, the researchers compare Obi trastuzumab with placebo combined with standard therapy LN effect .

Random trials have shown that type I anti- CD20 rituximab and orrelizumab failed to show benefit in proliferative lupus nephritis (LN) .

Orbituzumab is a humanized type II anti- CD20 monoclonal antibody, which is more effective than rituximab in inducing B cell depletion.
The results of a preclinical study showed that orbituzumab is better than rituximab Monoclonal antibodies are more effective in treating LN .
Therefore in this study, the researchers compare Obi trastuzumab with placebo combined with standard therapy LN effect .

LN patientstreated with mycophenolate mofetil and corticosteroids were randomly assigned to the orbituzumab 1000 mg group or the placebo group, and were treated on the 1st day and 2 , 24 and 26 weeks, and followed up until the 104th week
.

The primary endpoint is the complete renal response (CRR) at week 52 .
Exploratory analysis of data up to 104 weeks .
Specify the alpha level as 0.
2 in advance .

LN patients       treated with mycophenolate mofetil and corticosteroids were randomly assigned to the orbituzumab 1000 mg group or the placebo group, and were treated on the 1st day and 2 , 24 and 26 weeks, and followed up until the 104th week

     A total of 125 patients were randomized , accept the blind infusion .

Obituzumab achieved CRR at week 52 (primary endpoint, 22 (35%) vs 14 (23%) placebo; percentage difference, 12% ( 95% CI -3.
4% to 28% ), p =0.
115 ); to 104 weeks (26 (41%) vs 14 (23%) ; percentage difference, 19% ( 95% CI 2.

     A total of 125 patients were randomized , accept the blind infusion .
Obituzumab achieved CRR at week 52 (primary endpoint, 22 (35%) vs 14 (23%) placebo; percentage difference, 12% ( 95% CI -3.
4% to 28% ), p =0.
115 ); to 104 weeks (26 (41%) vs 14 (23%) ; percentage difference, 19% ( 95% CI 2.
7% -35% ), p=0.
026 ) .

     Conclusion      Conclusion : As of 104 weeks, Obi trastuzumab in combination with standard therapy compared to standard therapy alone improved LN kidney patient's response

Source:

Source:

Furie RA, Aroca G, Cascino MD , et al B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

Annals of the Rheumatic Diseases  Published Online First: 06 October 2021.
doi: 10.
1136/annrheumdis-2021-220920

Furie RA, Aroca G, Cascino MD , et al B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Annals of the Rheumatic Diseases  Published Online First: 06 October 2021.
DOI: 10.
1136 / annrheumdis-2021-220920 , et Al Annals of Rheumatic Diseases the  message here